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ABSTRACT
Background
Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better 
clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment 
in molecular risk stratification has sought to overcome the performance ceiling encountered by methods 
restricted to traditional clinical parameters. However, replication of results has proven challenging and 
intratumoural heterogeneity (ITH) may confound attempts at tissue-based stratification. 
Methods
We investigated the influence of confounding ITH on the performance of a novel molecular prognostic 
model, enabled by pathologist-guided multiregion sampling (n=183) of geographically separated mccRCC 
cohorts from the SuMR trial (development, n=22) and the SCOTRRCC study (validation, n=22). Tumour 
protein levels quantified by Reverse Phase Protein Array (RPPA) were investigated alongside clinical 
variables. Regularised wrapper selection identified features for Cox multivariate analysis with overall 
survival as primary endpoint.
Results
The optimal subset of variables in the final stratification model were N-cadherin, EPCAM, Age, mTOR 
(NEAT). Risk groups from NEAT had markedly different prognosis in the validation cohort (log-rank 
p=7.62x10-7; Hazard Ratio (HR) 37.9, 95% confidence interval 4.1–353.8) and two year survival rates 
(accuracy=82%, Matthews correlation coefficient=0.62). Comparisons with established clinico-pathological 
scores suggest favourable performance for NEAT (Net Reclassification Improvement 7.1% vs IMDC, 25.4% 
vs MSKCC). Limitations include the relatively small cohorts and associated wide confidence intervals on 
predictive performance. Our multiregion sampling approach enabled investigation of NEAT validation when 
limiting the number of samples analysed per tumour, which significantly degraded performance. Indeed, 
sample selection could change risk group assignment for 64% of patients, and prognostication with one 
sample per patient performed only slightly better than random expectation (median logHR=0.109). Low 
grade tissue was associated with 3.5-fold greater variation in predicted risk than high grade (p=0.044).
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Conclusions
This case study in mccRCC quantitatively demonstrates the critical importance of tumour sampling for the 
success of molecular biomarker studies research where ITH is a factor. The NEAT model shows promise for 
mccRCC prognostication and warrants follow-up in larger cohorts. Our work evidences actionable 
parameters to guide sample collection (tumour coverage, size, grade), to inform the development of 
reproducible molecular risk stratification methods.
Keywords
Cancer – Tumour heterogeneity – Prognostic markers – Renal cell carcinoma – Tumour biomarkers
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BACKGROUND
There is great unmet need for better treatment and diagnosis of kidney cancer, which remains the most lethal 
of all genitourinary malignancies. Five year survival in renal cell cancer (RCC) is approximately 40% 
overall, 10% in metastatic disease [1,2]. Clear cell RCC (ccRCC) represents about 80% of cases and around 
one-third of patients present with metastasis. Current risk-stratification of advanced ccRCC uses clinico-
pathological scoring systems, for example the International Metastatic Database Consortium (IMDC) [3] and
Memorial Sloan-Kettering Cancer Centre (MSKCC) [4] scores. Molecular markers promise to overcome the 
performance plateau encountered by clinico-pathological variables; however, success rates have historically 
been low [5–8].
Sunitinib is a first-line treatment for metastatic ccRCC (mccRCC), doubling median progression-free
survival compared with older immunotherapies such as IL-2 and interferon-α [9,10]. Sunitinib targets 
tumour, endothelial cells and pericytes, where the mechanism of action includes competitive inhibition of 
multiple receptor tyrosine kinases (RTKs) [11,12]. Up to 70% of patients treated with sunitinib show little or 
no tumour response [10], although may derive a survival benefit, despite incurring significant toxicity. 
Improved algorithms are critically needed to guide treatment decisions for current and emerging modalities 
[6,7,13].
Advances in prediction of treatment response and prognostication may be severely hindered by 
intratumoural heterogeneity (ITH) [14–16]. Indeed, percutaneous biopsy of mccRCC is a poor guide for 
pathological assessment of prognostic features [17]. Development of tumour sampling approaches to capture 
ITH is key for discovery and validation of candidate molecular risk stratification algorithms [6,7,13,15]. We 
studied protein expression ITH in the context of mccRCC risk stratification, controlling for clinical variables,
and developed a novel prognostic model (NEAT) that compares well with established clinico-pathological 
scores. The variables selected in NEAT inform mccRCC biology and suggest sunitinib action directly on 
tumour growth signalling. We quantitatively show a dramatic effect of tumour sampling on NEAT 
performance in a validation cohort receiving current standard treatment and demonstrate parameters 
pertinent to the development of molecular diagnostic tools for cancer medicine. We present 
recommendations that guide tumour sample selection for biomarker research in order to overcome variability
in the presence of ITH. Indeed, sampling protocols may determine the success or failure of attempts to 
validate molecular biomarkers where ITH is a factor.
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METHODS
Cohorts and tissue samples
This study examined two geographically separated cohorts of mccRCC patients with multiregion tumour 
sampling (Table 1). Excluding necrotic tissue, 108 and 75 fresh-frozen samples respectively were analysed 
from development and validation cohorts. The development cohort was drawn from the SuMR phase II 
clinical trial of upfront sunitinib (NCT01024205, n=22, London [18]). The validation cohort were 
cytoreductive nephrectomy patients from the SCOTRRCC study and received standard of care treatment 
(validation, n=22, Scotland [1,19]). The development cohort received three cycles of sunitinib 50mg (4 
weeks on, 2 weeks off) prior to nephrectomy; following nephrectomy, the validation cohort received either 
sunitinib (n=8), similar targeted agents (n=3), or no drug (n=11). These cohorts were enriched for poor or 
intermediate prognosis patients, in line with the SuMR trial selection criteria [18]. Median follow-up time, 
defined as time of entry to death or last contact, was 22.0, 12.3 months respectively for the development, 
validation cohorts. Univariate Cox regression for mTOR and overall survival analysed an overlapping cohort
(n=45) which included an additional patient [20]. Comparisons of cohort characteristics used Mann-Whitney,
Fisher or binomial tests as appropriate, p-values were two-tailed and corrected for multiple hypothesis testing
[21]. Net Reclassification Improvement (NRI) confidence intervals were calculated using bootstrapping 
[22,23].
Multiregion tumour sampling
Details of multiregion tissue mapping and sample preparation are given in [24]. Briefly, samples taken 
forward for reverse phase protein array (RPPA) analysis were spatially separated and selected to represent 
morphological diversity across the tumour. Fresh frozen tumours were divided into spatially mapped 1cm3 
pieces; cryostat sections of each piece were examined to confirm ccRCC status and for morphological 
classification. Up to four samples per morphologically distinct region in each tumour were selected for 
protein extraction, each of these samples reflected circa 50-75mm3 of tissue.
Intratumoural protein expression variance in sunitinib-exposed and sunitinib-naïve cancers
Fifty-five protein targets were investigated by reverse phase protein array (RPPA), selected according to 
prior knowledge and validated antibody availability [20]. Each tumour sample analysed by RPPA reflected 
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50 to 75mg of lysed tissue taken from a 1cm3 spatially mapped region [24]. Protein extraction, RPPA slide 
spotting, immunofluorescence data acquisition, data processing and identification of four markers that had 
increased variance associated with sunitinib treatment (p <0.05) were described previously [20,25]. Briefly, 
1mg/ml lysates were spotted onto nitrocellulose slides using a robotic spotter and immunofluorescence 
imaging performed with an Odyssey scanner (Li-Cor Biosciences, USA). Image processing and logistic 
curve fitting to the RPPA dilution series employed MicroVigene software (VigeneTech, USA). Protein 
variance per tumour was estimated using batch-corrected, normalised RPPA expression values from 
multiregion sampling, comparing the ratio of mean-squared errors between sunitinib-exposed and sunitinib-
naïve cohorts per protein marker in an ANOVA framework. Statistical significance of variance differences 
was assessed using the F-test only when relevant assumptions held, assessed by the Lillefours and Fligner-
Kileen tests [20]. Ranking by the protein expression variance log-ratio between sunitinib-exposed and 
sunitinib-naïve tumours identified a further two proteins of potential interest where variance was greater than
at least one of the four significant  markers; these proteins did not meet F-test assumptions and so were not 
assessed in our previous work using the ANOVA framework. Therefore, six proteins (CA9, N-cadherin 
(CDH2), EPCAM, mTOR (MTOR), MLH1, BCL2) were candidate molecular variables input into feature 
selection (described in the section below). The antibodies used for these candidate variables are listed in 
Supplementary Table S1 [see Additional file 1].
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Table 1. Clinical characteristics of cohorts studied.
Cohort Total Development 
(SuMR) 
Validation 
(SCOTRRCC) 
Number of patients 44 22 22
Age, median (range)b 66.5 (38.2 – 79.3) 64.5 (44 – 78) 67.5 (38.2 – 79.3)
Overall survival (months)a: 
Median
Interquartile Range
Number censored
Modes (bimodal model)
16.2
9.1 – 25.9
22
10.6, 27.3
23.5 
14.8 – 29.8
10
10.2, 27.4
12.3
7.6 – 18.8
12
11.6, 27.5
Number of samples per tumourb
median (range)
4 (1–10) 4 (1–10) 4 (2–8)
Male gendera 29 15 14
Fuhrman gradea:      4
     3
     2
9
22
13
1
12
9
8
10
4
Stagea:                  T4
T3
T2
T1
4
33
6
1
4
13
4
1
0
20
2
0
Performance statusd:
KPS >80 (unavailable) 34 (1) 13 (0) 21 (1)
Anaemiaa,* (unavailable) 22 (2) 12 (0) 10 (2)
Raised calciuma (unavailable) 8 (7) 5 (0) 3 (7)
Raised LDHd (unavailable) 10 (15) 5 (0) 5 (15)
Neutrophil count >70% upper limit of 
normala (unavailable)
9 (2) 2 (0) 7 (2)
Platelet count >400a (unavailable) 12 (2) 6 (0) 6 (2)
VHL Mutationa 31 14 17
Renal response at surgery:
Partial Response
Stable Disease
-
-
2
20
-
-
Number of metastatic sitesa:
1
2
3
19
18
7
6
11
5
13
7
2
IMDC classa:    Intermediate
Poor
           Unavailable
26
16
2
12
10
0
14
6
2
MSKCC classa: 
              Favourable / Intermediate:
              Poor
              Unavailable
26
12
6
13
9
0
13
3
6
* Hb <130 (M), <110 (F) a p>0.05 b p<0.05 d p<10-4
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Selection of variables and multivariate modelling
Variables were selected for Cox proportional hazards regression to overall survival on the development 
cohort using wrapper feature selection with backward elimination regularised by Bayesian information 
criterion (BIC) [26,27]. Backward elimination iteratively removed a single feature (i.e. protein expression or 
a clinical parameter) at each step, selecting for the greatest improvement in BIC value. BIC regularisation 
seeks to balance the model complexity (number of parameters, including candidate features) against the 
model likelihood (fit to the data); therefore this approach removes features with smallest contribution to 
model likelihood while penalising redundancy. The selection procedure terminated with a final model when 
removing any single feature did not improve BIC. The 'coxph' and 'stepAIC' functions were used, 
respectively from the 'survival' and 'MASS' R libraries (with model complexity penalty specified for BIC) 
[28].
Comparison with established clinico-pathological scores
IMDC and MSKCC scores were calculated according to the relevant clinical parameters [3,4]. Sufficient data
were available to calculate IMDC score for 20/22 patients in the validation cohort, all of which fell into the 
'intermediate' or 'poor' categories. MSKCC score was used to group patients into a) favourable/intermediate 
and b) poor prognosis; sufficient data were available to classify 14/22 patients. A further two patients were 
on the borderline of intermediate or poor prognosis with MSKCC parameters due to missing data, but had 
short survival times and were assigned to the poor prognosis group. Therefore, two ambiguous values were 
resolved in favour of the MSKCC score performance, making comparison with NEAT more stringent; hence 
16/22 patients were assigned MSKCC scores. All patients in the development cohort had sufficient data for 
IMDC and MSKCC scoring. Reported Hazard Ratio (HR) for NEAT reflects stratification into either better 
or worse than average risk groups (i.e. classification threshold of logHR=0); this threshold was 
predetermined and not derived from exploratory data analysis. HR reported for IMDC, MSKCC follows the 
groupings described above.
Investigating stratification performance with reduced number of samples per tumour
In order to evaluate tumour sampling effects on NEAT performance, a subsampling procedure produced 
datasets taking a maximum number of tumour samples (MNTS) of 1, 2 or 3 per tumour (and thus per 
patient). This approach employed Sobol sampling [29]; please see Supplementary Methods in Additional File
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1 for further details. The selected tumour samples were used to calculate median protein expression per 
patient as input for the NEAT algorithm. Patient age was unchanged. The HR and log-rank p-value for 
stratification into 'high' and 'low' risk groups defined by NEAT logHR=0 were calculated. This analysis was 
performed on 106 datasets per MNTS examined, where each dataset represented a unique combination of 
samples across all patients in the validation cohort. Therefore every patient was represented in each of the 
106 datasets; thus 106 NEAT HR and log-rank p-values were generated for each MNTS, representing 
predictive performance distributions across the different tumour sample combinations.
RESULTS
Cohort characteristics
The two mccRCC cohorts were similar across many characteristics (Table 1), although statistically 
significant differences were identified for Karnofsky performance status, elevated lactate dehydrogenase and 
age. Clustering analysis of overall survival (OS) using regularised Gaussian Mixture Modelling for 
unsupervised cardinality selection identified two modes (clusters) in the combined cohorts (n=44, Figure 1). 
The longer survival cluster had median OS (mOS) of 27.3 months, matching the favourable or intermediate 
prognosis subgroups defined in pivotal studies. For example, the favourable subgroup reported for the 
MSKCC score had mOS of 30 months [4], mOS for the IMDC score intermediate subgroup was 27 months 
[3] and a further independent study reported mOS of 26 months for the favourable subgroup [30]. The 
shorter survival cluster had mOS of 10.6 months, which is similar to reported mOS values across poor and 
intermediate prognosis subgroups in the above studies [3,4,30]. Greater representation of the shorter survival 
cluster in the validation cohort was partly due to censoring and also arising from the drug response selection 
criterion for the development cohort [18]. However, survival times for the validation and development 
cohorts were not significantly different. Therefore, the population studied (n=44) has a bimodal OS 
distribution that aligns with subgroups identified in larger mccRCC cohorts [3,4,30].
The NEAT algorithm for risk stratification of metastatic renal cancer patients
A machine learning approach using regularised wrapper selection [27] with Cox multivariate analysis [26] on
the development cohort identified a novel model for mccRCC patient risk stratification by overall survival. 
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We hypothesised that proteins with increased intratumoural variance following therapy may function as 
markers of resistance or aggressiveness and so enable prognostication. Indeed, factors underlying changes in 
tumour composition with treatment include clonal selection and proteomic diversity across isogenic cell 
populations [16,31,32]. Twelve variables were examined, including six key clinical parameters (grade, 
gender, age, neutrophils, haemoglobin, IMDC score [3]) and values for six proteins where intratumoural 
variance was greater in sunitinib-exposed mccRCC. Prognostic variables automatically identified by 
machine learning were N-cadherin, EPCAM, Age and mTOR (NEAT), controlling for the above clinical 
parameters. Protein expression values for these markers in the development and validation cohorts are shown
in Figure 2. The resulting multivariate Cox proportional hazards model for the development cohort had 
likelihood ratio test p=1.18×10-4 and all selected variables were individually significant in the multivariate 
model (Table 2). 
Table 2. Multivariate Cox proportional hazards model for overall survival, fitted on the development 
cohort.
Feature HR (95% Confidence Interval) p
mTOR 1.04x10-8  (6.09x10-4 – 1.71x10-13) 0.001
EPCAM 44.7 (845.6 – 2.36) 0.011
N-Cadherin 7.53x103 (2.76x106 – 20.71) 0.003
Age 1.14 (1.27 – 1.02) 0.018
The interesting positive relationship of mTOR with survival was followed up in an overlapping cohort and 
was significant in univariate Cox regression (p=0.034). The proportional hazards assumption was not 
invalidated (Grambsch-Therneau test [33], Supplementary Table S2 [see Additional file 1]). Hazard ratio 
(HR) was calculated from relative protein expression values and age in years at diagnosis as follows:
Hazard Ratio = exp(8.927 N-cadherin + 3.800 EPCAM + 0.129 Age - 18.385 mTOR)
NEAT performed well on the geographically separated validation and development cohorts (Figure 3). This 
work reflects evidence level IB [34], where development used prospective clinical trial data and validation 
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was performed with patients that received current standard therapy. Concordance index (C-index) [35] values
for the NEAT, IMDC and MSKCC score risk groups in the validation cohort were respectively 0.77 (95% CI 
0.66-0.88), 0.76 (95% CI 0.60-0.92) and 0.64 (95% CI 0.54-0.75). Net Reclassification Improvement [22] 
values for NEAT on the validation cohort were 7.1% vs IMDC (95% CI -24.8%, 39.0%) and 25.4% vs 
MSKCC score (95% CI -25.7%, 76.5%), shown in Table 3.
Table 3. Performance characteristics of NEAT and clinico-pathological scores.
Cohort Percentage NRI (95% CI) HR (95% CI)
NEAT vs
IMDC
NEAT vs
MSKCC+
NEAT IMDC MSKCC
Validation 7.1a
(-24.8, 39.0)
25.4b
(-25.7, 76.5)
37.89
(4.1, 353.8)
7.317a
(1.54, 34.69)
14.39b
(1.24, 165.7)
Development 25.0
(-34.8, 84.8)
23.3
(-28.3, 74.9)
10.649
(1.35, 84.08)
1.378
(0.44, 4.36)
3.577
(1.00, 12.85)
Values reflect assignment of either high risk or low risk status (methods).
a n=20 due to data availability
b n=16 due to data availability
Tumour sampling is a critical limiting factor for validation of molecular stratification approaches  
The overall approach to investigate the effects of tumour sampling on predictive performance is summarised 
in Figure 4. Three distributions of NEAT hazard ratio and log-rank p-value were generated to reflect 
sampling 1, 2 or 3 regions per tumour in the validation cohort; these distributions capture NEAT performance
for different sample combinations taken across tumours and patients. For example consider three patients, 
each with RPPA data from four different tumour samples; if a single sample is taken from each patient for 
NEAT analysis there would be 43 (i.e. 64) unique combinations of tumour samples across the three patients. 
Validation power rose significantly at each increase in the number of tumour samples taken per patient and 
the full dataset with a median of four spatially separated samples per tumour appeared adequate, conferring 
good predictive power. NEAT overall performance on the validation cohort was poor when limited to a 
single tumour sample per patient, and was significantly impaired with two samples per patient (Figure 5A). 
In the single sample regime, stratification into good and poor prognosis groups was only just better than 
random expectation (median logHR=0.109, binomial p<10-322); strong statistical significance is due to the 
large datasets studied. Taking two samples per tumour gave improved stratification performance over a 
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single sample (median logHR=1.614, Mann-Whitney p<10-324), and substantial further improvement was 
found when taking three samples (median logHR=3.030, Mann-Whitney p<10-324). Application of NEAT to
different subsets of tumour samples per individual patient changed risk group assignment for 64% of the 
validation cohort (Figure 5B). Interestingly, the median variance in per-patient HR was 3.5-fold greater in 
low grade samples than high grade samples (Mann-Whitney p=0.044). In order to further investigate the 
independent prognostic power of individual tumour regions, we compared prediction using expression values
averaged across all available samples for each individual against the best possible results obtained using only
one sample per tumour. Validation using all of the available samples per tumour outperformed even the most 
predictive single sample taken (p<10-6).
DISCUSSION
This study examines the effect of sampling on the performance of a novel molecular prognostic approach, 
NEAT, using protein measurements from 183 regions across 44 mccRCC tumours.  The unique development 
cohort from the SuMR trial allowed for selection of proteins that had increased intratumoural expression 
variance with treatment; we hypothesised that these proteins may be markers of aggressiveness and therefore
useful in prognostication. Although the cohorts are relatively small, NEAT gave statistically robust 
stratification of the independent validation cohort by overall survival (Figure 3A). The trend for favourable 
NEAT performance relative to the IMDC, MSKCC scores would benefit from investigation in a larger cohort
and the good performance of IMDC relative to the MSKCC score aligns with previous work [3]. To our 
knowledge, the mccRCC cohorts analysed here are the largest available with RPPA data from pathologist-
guided, multiregion tumour sampling. Our approach to capture grade diversity is likely to better represent 
ITH than standard sampling methods. Furthermore, each sample analysed by RPPA reflects a large tissue 
volume (circa 50-75mm3) relative to standard approaches based on tissue sections from formalin-fixed 
paraffin embedded material such as Tissue Microarray analysis (<0.2mm3 per region). Therefore, the RPPA 
data analysed covers a higher proportion of the overall tumour volume relative to standard approaches. The 
sampling approaches may be an important enabling factor in NEAT reproducibility and hence good 
validation performance, despite the relatively small cohorts studied. The RPPA technique offers potential as a
quantitative alternative to IHC and has already been applied in a clinical setting through the CLIA facility 
certification process  [36,37]. The NEAT model might ultimately be applied to inform decision making and 
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patient management in several areas: a) monitoring and follow-up, b) recruitment into clinical trials with new
agents, c) treatment decisions, for example for patients on the borderline of receiving drug due to other 
factors and d) patient counselling. 
The NEAT development and validation cohorts were relatively small (n=44 total), which is 
associated with increased risk of type II error and wide confidence intervals on predictive performance. 
Cytoreductive nephrectomy is standard clinical practice and the use of upfront TKI treatment is variable, 
limiting recruitment of a uniform cohort (as was obtained from the SuMR clinical trial) for NEAT 
development. A further limiting factor on the size of cohorts in our study was the availability of appropriately
consented fresh-frozen material with multiregion sampling and pathology assessment for RPPA analysis. Our
approach to discover resistance biomarkers required multiregion sampling of tumour tissue from patients 
treated with upfront sunitinib tumours in order to enable comparison of candidate marker variance in 
sunitinib-exposed and sunitinib-naiive material. Therefore, the cohorts received different treatment regimens 
and also had significant differences in some clinical characteristics. NEAT performed well on both cohorts 
despite these differences, and so might be broadly useful for prognostication of mccRCC. Further study of 
NEAT performance on an independent upfront sunitinib cohort would be of interest to further explore 
potential clinical utility, such as to inform decision-making over performing a cytoreductive nephrectomy 
[38]. 
Subsampling of the multiregion RPPA data showed that validation of the NEAT prognostic model 
was critically dependent on the number of samples analysed per tumour. Indeed, the model's performance in 
risk stratification improved significantly at each increase in the number of tumour regions analysed (Figure 
5A). These results therefore evidence the benefit of more extensive tumour sampling both for biomarker 
development and also in validation studies where the sampling protocol may contribute to a reported lack of 
reproducibility. The efficacy of even the most promising tissue-based biomarkers is diminished by ITH [39] 
and identification of molecular predictors that are unaffected by ITH may be very challenging. Indeed, 
cancer biomarkers have historically suffered from a high attrition rate [8]. The available data provided for 
subsampling analysis of one, two and three samples per tumour; however, analysis with the full dataset 
(median of four samples) performed best. In principle, even higher sampling rates may be beneficial; several 
patients where >3 samples were taken, reflecting larger tumours, show considerable variation in HR even 
when large numbers of samples are analysed (Figure 5B). One patient where eight tumour regions were 
examined had substantial variation in NEAT HR even across subsets containing six samples. Therefore, the 
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influence of tumour sampling on predicted risk is clear for individual patients. These results also evidence 
benefit of sampling in proportion to tumour volume for molecular diagnostics. We found considerably 
greater variance in HR for low grade over high grade samples and so tumour biomarker studies would 
benefit from performing more extensive sampling of low grade regions. This result also underlines the 
additional information provided by NEAT. Indeed, the automatic feature selection process deprioritised grade
relative to molecular variables. Prognostication using all of the multiple tumour samples gave better risk 
stratification than provided by analysis of any single sample in isolation. Therefore, NEAT analysis with 
multiple tumour regions captures information unavailable in any single sample; this information may reflect 
adaptive potential arising from ITH [40] and also might include aspects of disease progression such as the 
degree of vascularisation, or the length of time since initial dissemination competence.
 With regard to the individual components of the NEAT model, the positive association of mTOR 
with overall survival was the strongest, most significant feature and was also found in univariate analysis of 
an overlapping cohort. The mTOR pathway is an important mediator of RTK growth signalling [41]. 
Improved prognosis associated with elevated mTOR in NEAT suggests that tumours dependent upon mTOR 
have enhanced sensitivity to sunitinib. Therefore, sunitinib may act directly on tumour cells to inhibit 
mccRCC growth, consistent with results in ovarian cancer that VEGF stimulates the mTOR pathway [42]. 
Additionally, the mTORC1 complex, which includes mTOR, exerts negative feedback on receptor tyrosine 
kinases (RTKs) to suppress proliferation and survival [41]; this negative feedback could enhance therapeutic 
RTK inhibition by sunitinib.  Notably, mTOR inhibitors are currently in clinical use (for example, 
everolimus), possibly in conjunction with sunitinib or similar agents. Our results suggest caution in co-
treating with mTOR inhibitors and sunitinib, resonating with the poor performance of everolimus followed 
by sunitinib in the RECORD-3 trial [43]. Consistent with previous results, for example [44,45], a significant 
negative association with survival was identified for N-cadherin, a canonical marker of Epithelial to 
Mesenchymal Transition. Additionally, N-cadherin is expressed by endothelial cells and so may also 
represent a surrogate for vascularisation [46]. Age is a known RCC prognostic factor that was not selected 
for the IMDC score [3,47,48]. Our analysis took age as continuous values, which may partly explain 
selection of this variable for the NEAT model and not in the IMDC analysis which dichotomised age at 60 
years [49].  The IMDC score was not selected by our machine learning approach, which implies that, in the 
development cohort, prognostic information captured by the IMDC score overlaps with that provided by the 
NEAT variables. High EPCAM expression is also associated with poor prognosis in NEAT and multiple 
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cancers [50,51], although reports link EPCAM with better prognosis in localised RCC, for example [52,53]. 
The contrasting association with survival for EPCAM in NEAT may be due to differences between advanced 
and localised ccRCC, technologies used and context-specific function, for example in signal transduction by 
nuclear localisation of the cleaved intracellular domain [54]. 
CONCLUSIONS
Multiregion sampling to capture mccRCC grade diversity enabled investigation of ITH impact on risk 
stratification with a novel protein-based prognostic model, NEAT (N-Cadherin, EPCAM, Age, mTOR). 
NEAT compares well with established clinico-pathological scores on a geographically separate independent 
validation cohort that received current standard therapy. Results show that evaluation or attempted use of any
molecular prognostic and predictive methods with few tumour samples will lead to variable performance and
low reproducibility. We demonstrate parameters (tumour coverage, size, grade) that may be used to inform 
sampling in order to enhance biomarker reproducibility, and results underline the critical importance of 
addressing heterogeneity to realise the promise of molecular stratification approaches. Through studies such 
as TRACERx [55], we anticipate that extensive multiregion sampling will become standard procedure for 
discovery and validation of molecular diagnostics across a range of cancer types.
Recommendations arising from our research include: a) biomarker validation studies should 
implement tumour sampling protocols that match as closely as possible to the discovery work; b) clinical 
biomarker research and ultimately front-line diagnostic approaches may benefit from greater tumour 
sampling rates; c) clinical parameters (including tumour grade, size, coverage) can guide sample selection 
and investigation of additional parameters to inform sampling may be useful; d) optimisation of tumour 
sampling rate and sample selection protocols are important research areas to enable advances in stratified 
cancer medicine.
ABBREVIATIONS
ITH: intratumoural heterogeneity HR: hazard ratio
mccRCC: metastatic clear cell renal cell cancer  RPPA: reverse phase protein array
ccRCC: clear cell renal cell cancer RCC: renal cell cancer
IMDC: international metastatic database consortium BIC: bayesian information criterion
MSKCC: memorial sloan-kettering cancer centre OS: overall survival
15
NEAT: N-cadherin EPCAM Age mTOR multivariate model mOS: median overall survival
MNTS: maximum number of tumour samples  RTK: receptor tyrosine kinase
SCOTRRCC: scottish collaboration on translational research into renal cell cancer
DECLARATIONS
Ethics approval and consent to participate
Ethical approval was obtained prior to commencing work. REC references: 07/Q0603/58 (East London and 
the City Research Ethics Committee 1), 10/S1102/68 (South East Scotland Research Ethics Committee 02) 
and 10/S1402/33 (East of Scotland Research Ethics Service).
Consent for publication
Not applicable
Availability of data and material
Data generated or analysed during this study are included in this published article and supplementary 
information files, as follows. The NEAT model, custom computer code and datasets for investigation of 
stratification performance using limited tumour samples per patient and are provided in Additional File 2, 
under the Creative Commons CC-BY-NC-SA license. Please see the 'README.md' data file within the 
Additional File 2 zip archive. Normalised multiregion sampling RPPA data, representing 183 regions and 55 
markers, is provided in Additional File 3. Key clinical data are provided in Additional File 4; all clinical data 
is anonymised. Any further data that may be required is available from the corresponding author upon 
reasonable request.
Competing interests
IMO, GDS, ALRL, DJH and TP have an ownership interest in a patent pending relating to the NEAT 
algorithm. TP has received speakers bureau honoraria from and is a consultant/advisory board member for 
GlaxoSmithKline and Pfizer, additionally recipient of commercial research grants from Pfizer. GDS has 
received speakers bureau honoraria from Pfizer.
16
Funding
We acknowledge financial support from the Royal Society of Edinburgh Scottish Government Fellowship 
cofunded by Marie Curie Actions (IMO), Carnegie Trust (50115; IMO, DJH, GDS), IGMM DTF (IMO, 
GDS), Medical Research Council (MC_UU_12018/25; IMO), Chief Scientist Office Scotland (ETM37; 
GDS, DJH), Cancer Research UK (Experimental Medicine Centre; TP, DJH), Renal Cancer Research Fund 
(GDS), Kidney Cancer Scotland (GDS), MRC Clinical Training Fellowship (AL), RCSEd Robertson Trust 
(AL), Melville Trust (AL).
Authors' contributions
IMO conceived and designed the data analysis, led the writing of the manuscript and was scientific lead for 
this study. IMO supervised ALRL who co-designed and implemented the data analysis. DJH, GDS, TP 
conceived, designed and implemented clinical aspects, also obtained ethical approval. DJH developed the 
RPPA discovery platform. GDS, DJH, contributed samples, clinical data and supervised FM, AL, PM who 
collected protein data (RPPA). AL also provided clinical data and MO'D contributed pathology review. TP 
provided clinical data and samples for analysis by RPPA. IMO, GDS, ALRL and DJH drafted the manuscript
and interpreted results. IMO, DJH, GDS, AL, TP obtained funding. All authors read and approved the 
manuscript.
Acknowledgements
Thanks to Professor Fei Ye, Dept. Biostatistics, Vanderbilt University, USA for critical reading of the 
manuscript.
17
REFERENCES
1. Stewart GD, O’Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D. What can 
molecular pathology contribute to the management of renal cell carcinoma? Nat. Rev. Urol. 
2011;8:255–65. 
2. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. Age-Adjusted Incidence, 
Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend 
Analysis. Eur. Urol. 2011;59:135–41. 
3. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External 
validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma 
Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141–8. 
4. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a Comparative 
Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. J. Clin. 
Oncol. 2002;20:289–96. 
5. Kim HL, Seligson D, Liu X, Janzen N, Bui MHT, Yu H, et al. Using protein expressions to 
predict survival in clear cell renal carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 
2004;10:5464–71. 
6. Galsky MD. A prognostic model for metastatic renal-cell carcinoma. Lancet Oncol. 2013;14:102–
3. 
7. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU Guidelines 
on Renal Cell Carcinoma: 2014 Update. Eur. Urol. 2015;67:913–24. 
8. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable 
diversity in biomarker failures. Cancer Res. 2012;72:6097–101. 
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall 
Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With 
Metastatic Renal Cell Carcinoma. J. Clin. Oncol. 2009;27:3584–90. 
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib 
versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2007;356:115–24. 
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In Vivo Antitumor 
Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth 
Factor and Platelet-derived Growth Factor Receptors Determination of a 
Pharmacokinetic/Pharmacodynamic Relationship. Clin. Cancer Res. 2003;9:327–37. 
12. Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L. Sunitinib: the first to arrive 
at first-line metastatic renal cell carcinoma. Adv. Ther. 2012;29:202–17. 
13. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell 
carcinoma. Ther. Adv. Urol. 2015;1756287215597647. 
14. Heppner G. Tumor Heterogeneity. Cancer Res. 1984;44:2259–65. 
15. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture 
and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 
2014;46:225–33. 
16. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat.
18
Rev. Cancer. 2012;12:323–34. 
17. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, et al. Percutaneous biopsy of 
primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: 
comparison with nephrectomy assessment. J. Urol. 2010;184:1877–81. 
18. Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, et al. The Outcome of 
Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal 
Cancer. Eur. Urol. 2011;60:448–54. 
19. Stewart GD, Riddick ACP, Rae F, Marshall C, MacLeod L, O’Mahony FC, et al. Translational 
research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide 
translational research infrastructure in renal cancer. The Surgeon. 2015;13:181–6. 
20. Stewart GD, O’Mahony FC, Laird A, Rashid S, Martin SA, Eory L, et al. Carbonic Anhydrase 9
Expression Increases with Vascular Endothelial Growth Factor–Targeted Therapy and Is Predictive 
of Outcome in Metastatic Clear Cell Renal Cancer. Eur. Urol. 2014;66:956–63. 
21. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under 
dependency. Ann. Stat. 2001;29:1165–88. 
22. Pencina MJ, Steyerberg EW, D’Agostino RB. Extensions of net reclassification improvement 
calculations to measure usefulness of new biomarkers. Stat. Med. 2011;30:11–21. 
23. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net Reclassification Indices 
for Evaluating Risk Prediction Instruments: A Critical Review. Epidemiology. 2014;25:114–21. 
24. O’Mahony FC, Nanda J, Laird A, Mullen P, Caldwell H, Overton IM, et al. The use of reverse 
phase protein arrays (RPPA) to explore protein expression variation within individual renal cell 
cancers. J. Vis. Exp. JoVE. 2013; 
25. Stewart GD, O’Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, et al. Sunitinib 
Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. Clin. Cancer Res. 
2015;21:4212–23. 
26. Cox D. Regression models and life tables. J. R. Stat. Soc. B. 1972;34:187–220. 
27. Kohavi R, John GH. Wrappers for feature subset selection. Artif. Intell. 1997;97:273–324. 
28. Venables WN, Ripley BD. Modern Applied Statistics with S. New York: Springer; 2010. 
29. Press WH, Teukolsky SA. Quasi (that is, Sub) Random Numbers. Comput. Phys. 1989;3:76–9. 
30. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al. Validation and 
extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with 
previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 2005;23:832–41. 
31. Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, et al. Non-Darwinian dynamics 
in therapy-induced cancer drug resistance. Nat. Commun. 2013;4:2467. 
32. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al. 
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct 
tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. 
33. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted 
residuals. Biometrika. 1994;81:515–26. 
19
34. Simon RM, Paik S, Hayes DF. Use of Archived Specimens in Evaluation of Prognostic and 
Predictive Biomarkers. J. Natl. Cancer Inst. 2009;101:1446–52. 
35. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: 
model specific population value and confidence interval estimation. Stat. Med. 2004;23:2109–23. 
36. Negm OH, Muftah AA, Aleskandarany MA, Hamed MR, Ahmad DAJ, Nolan CC, et al. Clinical
utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer 
Res. Treat. 2016;155:25–35. 
37. Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, et al. A phase 1 study of 
cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 
2015;121:1645–53. 
38. Lane BR, Derweesh IH, Kim HL, O׳Malley R, Klink J, Ercole CE, et al. Presurgical sunitinib 
reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. 
Urol. Oncol. Semin. Orig. Investig. 2015;33:112.e15-112.e21. 
39. Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, et al. Systematic evaluation of
the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. 
Eur. Urol. 2014;66:936–48. 
40. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. 
Br. J. Cancer. 2013;108:479–85. 
41. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–
93. 
42. Trinh XB, Tjalma W a. A, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, 
et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial 
ovarian cancer. Br. J. Cancer. 2009;100:971–8. 
43. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II Randomized 
Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line 
Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. J. Clin. 
Oncol. 2014;32:2765–72. 
44. Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H. Expression profile of N-
cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. 
Oncol. Rep. 2006;15:1181–4. 
45. Pantuck AJ, An J, Liu H, Rettig MB. NF-κB–Dependent Plasticity of the Epithelial to 
Mesenchymal Transition Induced by Von Hippel-Lindau Inactivation in Renal Cell Carcinomas. 
Cancer Res. 2010;70:752–61. 
46. Cavallaro U, Liebner S, Dejana E. Endothelial cadherins and tumor angiogenesis. Exp. Cell 
Res. 2006;312:659–67. 
47. Taccoen X, Valeri A, Descotes J-L, Morin V, Stindel E, Doucet L, et al. Renal Cell Carcinoma in
Adults 40 Years Old or Less: Young Age is an Independent Prognostic Factor for Cancer-Specific 
Survival. Eur. Urol. 2007;51:980–7. 
48. Sánchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young Age Is An 
Independent Prognostic Factor For Survival Of Sporadic Renal Cell Carcinoma. J. Urol. 
2004;171:2160–5.
20
49. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic Factors 
for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular 
Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. J. Clin. 
Oncol. 2009;27:5794–9. 
50. Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, et al. EpCAM expression in 
primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 
2011;64:415–20. 
51. Trzpis M, McLaughlin PMJ, de Leij LMFH, Harmsen MC. Epithelial cell adhesion molecule: 
more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007;171:386–95. 
52. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MHT, et al. Epithelial Cell Adhesion 
Molecule (KSA) Expression Pathobiology and Its Role as an Independent Predictor of Survival in 
Renal Cell Carcinoma. Clin. Cancer Res. 2004;10:2659–69. 
53. Eichelberg C, Chun FK, Bedke J, Heuer R, Adam M, Moch H, et al. Epithelial cell adhesion 
molecule is an independent prognostic marker in clear cell renal carcinoma. Int. J. Cancer J. Int. 
Cancer. 2013;132:2948–55. 
54. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-
associated antigen EpCAM. Nat. Cell Biol. 2009;11:162–71. 
55. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking Genomic 
Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biol. 
2014;12:e1001906. 
21
FIGURE LEGENDS
Figure 1: Overall survival distributions for the development (SuMR) and validation (SCOTRRCC) 
cohorts. Kernel density plots are shown for all survival data, including censored. The above distributions 
indicate bimodality for both cohorts studied, with similar mode positions around 11 and 27 months. These 
survival modes align with survival subgroups reported in pivotal studies [3,4,30]. The development cohort 
(blue) had the greatest proportion of patients in the mode centred around 27 months, reaching density value 
of 0.037. The majority of patients in the validation cohort (red) are in the survival mode around 11 months 
(reaching density value of 0.049), partly due to greater censoring in this cohort. 
Figure 2. Expression values for NEAT molecular features. Protein concentration values determined by 
RPPA for validation (yellow) and development (blue) cohorts are shown for all samples (log2), including 
multiple datapoints per tumour. Therefore a single tumour may contribute datapoints across the full range of 
expression values shown in each box-plot. Relative expression values increase from the bottom (-9) to the 
top (-5.2) of the y-axis. The distributions are overlapping, with a shift towards higher expression in the 
development cohort.
Figure 3. Kaplan-Meier curves for overall survival risk stratification by N-Cadherin, EPCAM, Age 
and mTOR (NEAT).
(A) Validation cohort. The high risk (n=4, dashed line) and low risk (n=18, dotted line) groups identified by 
NEAT have markedly different prognosis (log-rank p=7.62x10-7) with respective two year survival rates of 
0% and 78% (precision=100%, recall=50%, specificity=100%, accuracy = 82%, Matthews correlation 
coefficient=0.62). Data analysed were independent of wrapper feature selection and of fitting model 
coefficients.
(B) Development cohort. The identified features and model coefficients were learned on the data shown, 
which therefore does not provide an independent test. High risk (n=14, dashed line) and low risk (n=8, dotted
line) groups are clearly separated (log-rank p=0.00553), with respective two-year survival rates of 43% and 
100%. (precision=57%, recall=100%, specificity=57%, accuracy =73%, Matthews correlation 
coefficient=0.57).
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Figure 4. Overall approach for investigation of the effect of subsampling on NEAT predictive 
performance. A total of 106 combinations of n={1,2,3} samples per tumour were analysed across the 22 
patients in the validation cohort where multiregion sampling encompassed identified morphological 
intratumoural heterogeneity (top left). A median of four samples were taken per tumour. The distributions of 
logHR and log-rank p-values across the 106 samples taken for each value of n (bottom right) are given at 
readable size in Figure 5.
Figure 5. Stratification of the validation cohort critically depends upon tumour sampling.
(A) Values of NEAT logHR (top) and p-values (log-rank test, bottom) are shown for subsampled datasets 
generated by taking a maximum of one (dashed line), two (dotted line) or three (dot-dash line) samples per 
tumour. The vertical line in each graph indicates NEAT performance using all available samples. 
Stratification performance improves significantly as the number of samples taken increases.
(B) Variation in per-patient NEAT HR driven by tumour sampling. Each plot corresponds to a patient and 
shows the distribution of logHR from NEAT across the available tumour samples. Vertical bars indicate 
logHR range for every possible combination of the specified number of samples. Therefore, logHR 
calculated using all samples is shown on the right of each plot as a single point. For many patients (14/22, 
64%) the logHR distribution encompasses the classification threshold (logHR=0); hence risk group 
assignment is critically influenced by the tumour sample(s) analysed.
ADDITIONAL FILES
Additional File 1: Supplementary methods, tables and summary of the Additional File 2 zip archive (PDF).
Additional File 2:  NEAT model, custom computer code and relevant datasets for investigation of limiting 
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Additional File 3: Reverse phase protein array data for multiregion tumour sampling (Comma Separated 
Values, CSV).
Additional File 4: Clinical data, columns are: anonymised patient identifier, age, grade, event, overall 
survival, Heng class, MSKCC class. Anonymised identifiers correspond with those given in Additional File 3
(Comma Separated Values, CSV).
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